Identification of BIK As an Unfavorable Prognostic Marker and Novel Therapeutic Target in Microsatellite Stable Colorectal Cancer Harboring KRAS Mutations

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2022 Dec 12

PMID 36504908

Authors

Peng Liu

Feng Jiao

Zhenghua Zhang

Feilong Zhao

Jinping Cai

Shiqing Chen

Tao Fu

Min Li

Affiliations

Soon will be listed here.

Abstract

mutations lead to persistent activation of multiple downstream effectors that drive the cancer phenotype. Approximately 30%-50% of colorectal cancer (CRC) patients harbor mutations, which confer more aggressive tumor biology and shorter overall survival (OS), especially in microsatellite stable (MSS) metastatic CRC. Given that KRAS mutant protein has been proven difficult to target directly, identifying genes that function closely with and targeting these genes seems to be a promising therapeutic strategy for -mutated MSS CRC. Here, function-sensitive genes were identified by assessing the correlation between gene dependency scores from CRISPR knockout screens and mRNA expression in -mutated MSS CRC cell lines in the Cancer Cell Line Encyclopedia (CCLE) database. If the correlation coefficient was ≥ 0.6, the gene was considered a function-sensitive gene. Then function-sensitive genes related to prognosis were screened out in The Cancer Genome Atlas (TCGA) cohort, and the prognostic value was validated in the Gene Expression Omnibus (GEO) cohort. Single-sample gene set enrichment analysis (ssGSEA) was performed to investigate the potential mechanisms. PockDrug-Server was used to predict the druggability of candidate genes. The results showed that in 20 -mutated MSS CRC cell lines, 13 genes were identified as function-sensitive genes. Of these 13 genes, only BIK expression was significantly associated with progression-free survival (PFS) and OS, and the BIK-high patients had significantly poorer PFS (HR=3.18, P=0.020) and OS (HR=4.74, P=0.030) than the BIK-low patients. Multivariate Cox regression analysis revealed high BIK expression as an independent predictor for poorer prognosis in -mutated MSS CRC. The prognostic value of BIK was also successfully validated in a GEO cohort. The results of ssGSEA showed that the BIK-high group was more prone to strong metastasis activity than the BIK-low group. Pocket druggability prediction analysis presented that BIK had three druggable pockets, and their druggability scores were above 0.8. These findings suggested that BIK is a promising prognostic marker and therapeutic target in -mutated MSS CRC.

References

Teixeira O, Lacerda P, Froes T, Nonato M, Castilho M . Druggable hot spots in trypanothione reductase: novel insights and opportunities for drug discovery revealed by DRUGpy. J Comput Aided Mol Des. 2021; 35(8):871-882. DOI: 10.1007/s10822-021-00403-8. View

Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G . KRAS Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020; 383(13):1207-1217. PMC: 7571518. DOI: 10.1056/NEJMoa1917239. View

Wisinski K, Tevaarwerk A, Burkard M, Rampurwala M, Eickhoff J, Bell M . Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res. 2016; 22(11):2659-67. PMC: 4891227. DOI: 10.1158/1078-0432.CCR-15-2365. View

Le D, Kim T, Van Cutsem E, Geva R, Jager D, Hara H . Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2019; 38(1):11-19. PMC: 7031958. DOI: 10.1200/JCO.19.02107. View

Hamidi H, Ivaska J . Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018; 18(9):533-548. PMC: 6629548. DOI: 10.1038/s41568-018-0038-z. View

Abi Hussein H, Borrel A, Geneix C, Petitjean M, Regad L, Camproux A . PockDrug-Server: a new web server for predicting pocket druggability on holo and apo proteins. Nucleic Acids Res. 2015; 43(W1):W436-42. PMC: 4489252. DOI: 10.1093/nar/gkv462. View

Salazar R, Garcia-Carbonero R, Libutti S, Hendifar A, Custodio A, Guimbaud R . Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2017; 23(7):766-e90. PMC: 6058330. DOI: 10.1634/theoncologist.2017-0144. View

Ryan M, Corcoran R . Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018; 15(11):709-720. DOI: 10.1038/s41571-018-0105-0. View

Tan C, Du X . KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol. 2012; 18(37):5171-80. PMC: 3468848. DOI: 10.3748/wjg.v18.i37.5171. View

10.

Hofmann M, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek J . BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov. 2020; 11(1):142-157. PMC: 7892644. DOI: 10.1158/2159-8290.CD-20-0142. View

11.

Yang Y, Yu B, Zhang X, Zhu Y . Identification of TNIK as a novel potential drug target in thyroid cancer based on protein druggability prediction. Medicine (Baltimore). 2021; 100(16):e25541. PMC: 8078263. DOI: 10.1097/MD.0000000000025541. View

12.

Nichols R, Haderk F, Stahlhut C, Schulze C, Hemmati G, Wildes D . RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018; 20(9):1064-1073. PMC: 6115280. DOI: 10.1038/s41556-018-0169-1. View

13.

Pandya V, Glubrecht D, Vos L, Hanson J, Damaraju S, Mackey J . The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer. Oncotarget. 2016; 7(22):33272-85. PMC: 5078093. DOI: 10.18632/oncotarget.8924. View

14.

Siddiqa M, Rao D, Suvarna G, Chennamachetty V, Verma M, Rao M . In-Silico Drug Designing of Spike Receptor with Its ACE2 Receptor and Nsp10/Nsp16 MTase Complex Against SARS-CoV-2. Int J Pept Res Ther. 2021; 27(3):1633-1640. PMC: 7966892. DOI: 10.1007/s10989-021-10196-x. View

15.

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

16.

Hamza M, Ali A, Khan S, Ahmed S, Attique Z, Rehman S . nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of and hydroxychloroquine. J Biomol Struct Dyn. 2020; 39(11):4089-4099. PMC: 7332867. DOI: 10.1080/07391102.2020.1778534. View

17.

Ramsay A, Marshall J, Hart I . Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 2007; 26(3-4):567-78. DOI: 10.1007/s10555-007-9078-7. View

18.

Sepulveda A, Hamilton S, Allegra C, Grody W, Cushman-Vokoun A, Funkhouser W . Molecular Biomarkers for the Evaluation of Colorectal Cancer. Am J Clin Pathol. 2017; 147(3):221-260. PMC: 7263311. DOI: 10.1093/ajcp/aqw209. View

19.

Popat S, Hubner R, Houlston R . Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23(3):609-18. DOI: 10.1200/JCO.2005.01.086. View

20.

Koopman M, Kortman G, Mekenkamp L, Ligtenberg M, Hoogerbrugge N, Antonini N . Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009; 100(2):266-73. PMC: 2634718. DOI: 10.1038/sj.bjc.6604867. View